The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.
Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies.
Mikesch
Jan-Henrik
JH
Department of Haematology-Oncology, University of Muenster, Germany.
Schier
Kathrin
K
Roetger
Antje
A
Simon
Ronald
R
Buerger
Horst
H
Brandt
Burkhard
B
D015703:Antigens, CD / Q000378:metabolism; D018958:CD55 Antigens / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D019000:Phosphotyrosine / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D015398:Signal Transduction
C095004:ADGRE5 protein, human; D015703:Antigens, CD; D018958:CD55 Antigens; D008024:Ligands; D008562:Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled; D019000:Phosphotyrosine